



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey
Eldora L. Ellison
Donald R. Banowitz
Peter A. Jackman

Brian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Edward W. Yee
Grant E. Reed
Virgil Lee Beaston
Theodore A. Wood
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon

Laura A. Vogel
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
W. Blake Coblenz
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler Jenks
Paul A. Calvo
C. Matthew Rozier*
Shameek Ghose
Jenny J. Yeh

Randall K. Baldwin
Daniel J. Nevriy
Lori M. Brandes
Jeffrey K. Mills*
Mita Mukherjee*
Scott M. Woodhouse*
Christian A. Camarce*
Richard D. Collier III*
Bonnie Nannenga-Combs
Alyssa K. Sandrowitz*
Ishan P. Weerakoon*

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Peter A. Socaras
Danielle L. Letting
Steven C. Oppenheimer
Aaron S. Lukas

Gaurav Asthana
Stephanie L. Elmer
Robert E. Bakin
Salvador M. Bezos
Yasser Mourtada

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

February 27, 2008

WRITER'S DIRECT NUMBER:

(202) 772-8625

INTERNET ADDRESS:

ESTEFFE@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1645

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/799,072; Filed: March 12, 2004
For: **Genes and Proteins, and Their Use**
Inventors: HUGHES *et al.*
Our Ref: 2479.032000J/EKS/C-K

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Third Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Two (2) sheets of Form (PTO/SB/08A) listing the cited documents (US8-US11 and FP10-FP26);
3. One (1) sheet of Form (PTO/SB/08B) listing cited document (NPL5); and
4. Copies of seventeen (17) cited documents (FP10-FP26).

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
February 27, 2008
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Eric K. Steffe", written over the printed name.

Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

EKS/C-K/SIA/tvw
Enclosure(s)

783017_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HUGHES *et al.*

Appl. No.: 10/799,072

Filed: March 12, 2004

For: **Genes and Proteins, and Their Use**

Confirmation No.: 9134

Art Unit: 1645

Examiner: BASKAR, Padmavathi

Atty. Docket: 2479.032000J/EKS/C-K

**Third Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on October 30, 2007, in connection with the above-captioned application.

Copies of documents, **FP10** to **FP26**, are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, cited on the attached IDS Form PTO/SB/08A as documents **US8** to **US11**, are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3)A, Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document, **FP13**, cited on Forms PTO/SB/08A:

Document **FP13**, WO 01/77335 A2, is in the French language. An English language abstract of document FP13 can be found on the face page of the published patent application.

Furthermore, a copy of document **NPL5** is not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is sua sponte waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following co-pending and co-owned U.S. Patent applications:

U.S. Non-Provisional Patent Application No. 11/321,475 (Atty. Dkt. No. 2479.0330006), inventors Hughes *et al.*, filed December 29, 2005, published as US 2006/0104990 A1, cited as document **US10** and

U.S. Non-Provisional Patent Application No. 11/892,013 (Atty. Dkt. No. 2479.0330007), inventors Hughes *et al.*, filed August 17, 2007, pending and cited as document **NPL5**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 2/27/08

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
771530_1